Matinas BioPharma Holdings, Inc. (MTNB) Financials

MTNB Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 29.8 million 6.6 million
June 30, 2023 34.0 million 6.2 million
March 31, 2023 38.3 million 5.6 million
Dec. 31, 2022 44.8 million 8.2 million

MTNB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -4.4 million 1.2 million
June 30, 2023 -2.4 million 1.2 million
March 31, 2023 -4.1 million 1.3 million
Dec. 31, 2022 -4.3 million 1.3 million

MTNB Net Income

No data available :(

MTNB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 18.2 million - 3.7 million
June 30, 2023 22.5 million - 3.9 million
March 31, 2023 24.9 million - 4.0 million
Dec. 31, 2022 28.8 million - 4.1 million

MTNB Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 217.3 million
June 30, 2023 217.3 million
March 31, 2023 217.3 million
Dec. 31, 2022 216.8 million

MTNB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 16000 3.3 million 2.8 million -
June 30, 2023 202000 3.6 million 2.6 million -
March 31, 2023 202000 4.0 million 2.7 million -
Dec. 31, 2022 41601 3.9 million 2.7 million -

MTNB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 238000
June 30, 2023 - 234000
March 31, 2023 1.1 million 229000
Dec. 31, 2022 1.1 million 3.5 million

MTNB

Price: $0.78

52 week price:
0.48
3.09

Earnings Per Share: -3.42 USD

P/E Ratio: -0.18

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 237100

Market Capitalization: 3.8 million

Links: